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Abstract
Background: Burkholderia contaminans is an emerging pathogen in the cystic fibrosis (CF) setting. Included in the
Burkholderia cepacia complex (Bcc), B. contaminans is a Gram negative, motile, obligate aerobe previously classified
as a pseudomonad. Previous reports have described B. contaminans isolation from patients in Portugal, Switzerland,
Spain, Argentina and the USA. This, however, is the first report relating to B. contaminans affecting Irish patients
with CF, initially detected in a paediatric setting.
Case presentation: Burkholderia contaminans was identified in the routine analysis of sputum from a fourteen year
old boy, at his annual review and subsequently from the sputum from his 19 year old brother. RecA gene
sequencing and pulsed field gel electrophoresis (PFGE) were unable to distinguish between the isolates, which
demonstrated with susceptibility to ciprofloxacin, cotrimoxazole, meropenem, pipercillin/tazobactam and
ceftazidime. Both isolates were resistant to aztreonam, with reduced susceptibility to tobramycin. Following
treatment with intravenous meropenem and ceftazidime, oral ciprofloxacin and nebulised tobramycin for 6 weeks,
sputum specimens from both patients were negative for B. contaminans. No other member of the local CF cohort
proved positive.
Conclusions: Bcc bacteria are associated with poor prognosis in CF and decreased life expectancy, specifically
leading to a more rapid decline in lung function and, in some cases, to a fatal necrotizing pneumonia known as
the “cepacia syndrome”. Some species exhibit innate resistance to multiple antimicrobial agents and their
transmission rate can be high in susceptible patients. In that context, we describe the first incidence of CF-related B.
contaminans in Ireland and its successful eradication from two patients, one paediatric, using an aggressive
antimicrobial regimen.
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Background
Burkholderia cepacia complex (Bcc) is a grouping of bac-
teria comprising at least 17 species capable of infecting
susceptible patients including the immunocompromised
and those with cystic fibrosis (CF) [1, 2]. Burkholderia
contaminans is one such species, first identified as a
contaminant of a marine-derived nucleic acid sample
obtained from the Sargasso Sea [3, 4]. Burkholderia
contaminans is increasingly associated with CF [5–11]
although not exclusively as other hospitalised non-CF
patients have also been affected [9, 12–14].
Globally, Ireland has the highest prevalence of CF (a
recessive autosomal disease associated with increased
susceptibility to respiratory infection) with prevalence of
2.98 per 10,000 compared to European and USA preva-
lence of 0.737 and 0.797 per 10,000, respectively [15]. In
that context, this first detection of B. contaminans in
any Irish patient and, especially CF patients, is note-
worthy. In this report, similar to other studies involving
B. contaminans, we attempt to correlate colonisation
with incidence of acute exacerbation of symptoms. In
addition, we describe the outcomes of molecular typing
of the isolates, using recA sequencing and pulsed field
gel electrophoresis (PFGE) techniques successfully
employed elsewhere [6, 16, 17]. As B. contaminans is
emerging as an identifiable, discrete pathogen described
previously as “virtually impossible to eradicate from the
CF lung, posing a serious clinical threat” [8] and is
currently without definitive guidelines for antimicro-
bial sensitivity/resistance, we detail our antimicrobial
susceptibility testing, and the successful eradication of
B. contaminans from both patients using an aggressive
treatment regimen.
Case presentation
In August 2013, two male CF patients, siblings aged 14
and 19 were identified as Burkholderia contaminans
positive at University Hospital, Limerick, Ireland (where
the first Irish CF-related multidrug-resistant Bordetella
petrii was identified) [18]. Retrospective analyses of
patient charts and stored sputum samples determined
frequency of hospitalisation, episodes of infections, and
antimicrobial use prior to B. contaminans detection and
throughout treatment. Emphasis was placed on pres-
ence/absence of clinical features during treatment, in
particular lung function, efficacy of antimicrobial therapy
and patient outcome.
Genotypically, Patients A (aged 14) and B (19 years)
are homozygous for the F 508del mutation (within the
CF transmembrane conductance regulator causing loss
of the amino acid phenylalanine, affecting chloride ion
channels in cell membranes and leading to production
of thickened mucus). Both resided in the family home in
the Midwest of Ireland.
Between diagnosis as a neonate and August 2013,
14 year old Patient A had experienced four admissions
for treatment of exacerbations of CF, complicated by re-
active airways disease with persistent cough and poor
compliance with his medications and adherence to
physiotherapy. Prior to August 2013, his cough swabs
and sputum cultures had yielded Staphylococcus aureus,
Haemophilus parainfluenzae, Candida species and As-
pergillus fumigatus. He had also acquired, and had been
treated for, Pseudomonas aeruginosa in 2008, which re-
curred in 2012. Attempts to eradicate P. aeruginosa failed
and he was deemed to be chronically infected in November
2012. As the strain was resistant to tobramycin, he was
commenced on long-term anti-pseuodomonad therapy
comprising alternate months of two mega-units of nebu-
lised colistin twice daily with 75 mg of nebulised aztreonam
three times daily, along with oral azithromycin 250 mg
once daily taken three times per week. Struggling with
adherence, his Forced Expiratory Volume in 1 s (FEV1)
dropped from 62 % in August 2012 to 46 % in June 2013.
On 6th August 2013, Patient A presented for annual
review. Staphylococcus aureus and P. aeruginosa were
identified from his routine sputum sample. In addition,
however, Burkholderia contaminans was also detected,
representing the first such incidence in Ireland. Patient
A’s FEV1 was 38 %, his lowest recorded. His full blood
count at the time showed a mildly elevated white cell count
of 10.45 109/L, with a neutrophil count of 5.86 109/L.
Between diagnosis as a neonate and August 2013,
19 year old Patient B had also demonstrated poor com-
pliance with his treatment regimen, complicated by insu-
lin dependent diabetes mellitus and pulmonary fibrosis.
Like his younger brother, Patient B’s cough swabs and
sputum cultures had consistently yielded varying and
mixed species: H. parainfluenzae, H. influenzae, S. aur-
eus, Streptococcus pneumoniae, and A. fumigatus. In
2007, he acquired Pseudomonas aeruginosa (tobramycin
resistant) and, despite multiple attempts at eradication,
he became chronically infected. His FEV1 fluctuated be-
tween 17 and 95 % throughout this time, with a baseline
of 68 %. His antimicrobial medications included oral azi-
thromycin 250 mg 3 days per week and two mega-units
nebulised colistin twice daily, on alternate months.
On 2nd July 2013, Patient B was admitted with an in-
fective exacerbation and was treated with a course of
intravenous meropenem (2 g every 8 h) and tobramycin
(480 mg once daily) combined with intense physiother-
apy. He was also provided nutritional support for a body
mass index of 17. Two days after detection of B. contam-
inans in Patient A’s sputum, his brother was confirmed
as positive.
Microbiological analysis was comprehensive, utilising
recA sequencing and pulsed field gel electrophoresis
(PFGE). More specifically, following growth of bacteria
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on “Burkholderia cepacia specific agar” (LIP Diagnostics,
Fannin Healthcare, Ireland), identification was confirmed
by Matrix-Assisted Laser-Desorption/Ionization Time-
Of-Flight Mass Spectrometry (MALDI-TOF MS) and
samples forwarded to the Antimicrobial Resistance and
Healthcare Associated Infections Reference Unit (AMR-
HAI, Public Health England) for confirmation by ampli-
fication of the recA gene using the BCR1 and BCR2
primers described previously [19]. Pulsed-field gel elec-
trophoresis (PFGE) of XbaI-digested genomic DNA was
also performed. Both methods indicated presence of a
single discrete B. contaminans strain.
Currently, there is no definitive classification of B. con-
taminans as sensitive/resistant to specific antimicrobials.
In this study, the efficacy of selected antimicrobials
against the B. contaminans isolates was initially assessed
using Etest® (bioMérieux, France) test strips to ascertain
minimum inhibitory concentrations (MIC): aztreonam
MIC >256 mg/L; meropenem MIC = 2.0 mg/L; colisti-
methate >256 mg/L; tobramycin = 64 mg/L; ciprofloxa-
cin = 1 mg/L; pipercillin/tazobactam MIC >256 mg/L;
and ceftazidime MIC = 8 mg/L. Both isolates were sent
to the UK CF microbiology reference laboratory at the
Freeman Hospital (Newcastle upon Tyne) for synergy
testing (i.e., determining the optimal antimicrobial com-
binations to eradicate infection). A combination of
tobramycin and meropenem achieved only inhibition of
growth, while combinations of ceftazidime with merope-
nem, ciprofloxacin, and tobramycin proved bactericidal.
It was decided to adopt a 6 week quadruple treatment
strategy comprising IV ceftazidime 50 mg per kg per
dose every 8 h, IV meropenem 40 mg per kg per dose
[to a maximum of 2 g per dose], oral ciprofloxacin
15 mg per kg per dose bd, and nebulised tobramycin
300 mg bd. However, Patient A discontinued merope-
nem at 3 weeks as a consequence of developing severe
back and muscle pain, a reaction that was reported to
the Regulatory Agency. He completed treatment with
the remaining three antimicrobials and his FEV1 im-
proved from 38 to 61 %. He was subsequently treated
with nebulised aztreonam and colistimethate, alternating
monthly for a year. Patient B successfully completed the
initial regimen over 6 weeks, with similar improvement
reflected in an cumulative increase in FEV1 of 26 % over
the subsequent 1 year period, along with an increase in
weight from 54 kg in July 2013 to 61.9 kg in September
2014. Burkholderia contaminans has been eradicated
successfully from both patients, and they remain free of
infection 30 months post treatment. Both patients now
demonstrate increased adherence to treatment and
physiotherapy, with sustained improved lung function.
At the time of B. contaminans detection, Patient A
was attending the paediatric clinic while his brother was
admitted to the adult CF clinic. The clinics are located
in separate areas of the hospital. However, upon identifi-
cation of the pathogen, the local Bcc infection control
policy was implemented and the brothers were segre-
gated from all other CF patients. Containment appears
to have been effective as B. contaminans has not been
detected in our hospital since.
Conclusions
Species of the Burkholderia cepacia complex are associ-
ated with opportunistic infection in patients with CF,
and are associated with a worse prognosis and decreased
life expectancy [10]. One such bacterium is B. contami-
nans that, since first identification in 2009, has become
recognized as ubiquitous in the environment [20, 21],
including healthcare facilities where it has caused out-
breaks [12, 14, 22]. However, the discrete impact of B.
contaminans is poorly understood as, firstly, its inci-
dence is typically reported as part of multi-bacterial in-
fections [10] and, secondly, its presence may not have
been identified at all pre-2009 or, since then, the species
incorrectly identified using available molecular tech-
niques [23]. Indeed, it is noticeable that recent studies of
B. contaminans have, in many cases, focused on devel-
opment of accurate and more sophisticated molecular
characterization of the species including mechanisms
mediating its pathogenicity [5, 24–26]. However, it is
somewhat ironic that some of those studies are focused
on developing novel antimicrobial/antifungal agents pro-
duced by B. contaminans [27–29].
In this report, we describe the first clinical incidence
of B. contaminans in Ireland. As with others, our obser-
vation related to CF patients, one of whom was a child.
Given the high prevalence of CF in Ireland, and the in-
creasingly frequent isolation of B. contaminans from CF
patients in some countries (e.g., [11], our reaction to
identification of the pathogen for the first time was one
of extreme prudence. Our empiric, and subsequently tar-
geted, antimicrobial treatment regimen was deliberately
aggressive, as was our Bcc infection control policy. Ul-
timately, both proved effective, resulting in eradication
of the Burkholderia strain from the two patients and
containment of the potential risk to other CF patients
attending the hospital.
Further, given the current lack of defined guidelines
regarding B. contaminans antimicrobial susceptibilities,
we present our MIC data (detailing resistance to aztreo-
nam and tobramycin and susceptibility to ciprofloxacin,
cotrimoxazole, meropenem, pipercillin/tazobactam and
ceftazidime) to supplement results published recently
from Switzerland [30]. We hope that our descriptions of
the cases and our successful treatment choices will prove
useful to clinicians encountering B. contaminans and
prove beneficial to them and their patients.
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